Enveric Biosciences to Participate in Upcoming Investor Conferences in September 2021

NAPLES, Fla., Sept. 20, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform for the mind and body using psychedelics and cannabinoids, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in two upcoming investor conferences:

Maxim's Advances in Mental Health Virtual Conference
Wednesday, September 22^nd at 10:00 a.m. ET
Panel titled: Next Gen Psychedelics: Novel Chemical Entities
To attend, register here

Benzinga's Healthcare Small Cap Virtual Conference
Thursday, September 30^th at 3:40 p.m. ET
To attend, register here

For more information about the conferences, or to schedule a one-on-one meeting with Enveric's management, please contact your appropriate representative directly, or send an email to Maxim at [email protected], Benzinga at [email protected], or KCSA Strategic Communications at [email protected].

About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric's robust pipeline supports drug development from the clinic to commercialization for millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more. For more information, please visit www.enveric.com.

Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
212.896.1254 / 212.896.1267
[email protected] / [email protected] 

Media Contacts
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
212.896.1241 / 212.896.1204
[email protected] / [email protected] 

SOURCE Enveric Biosciences

Related Links

http://www.enveric.com